Compare LCUT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | ARMP |
|---|---|---|
| Founded | 1945 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.1M | 156.4M |
| IPO Year | 1996 | 1996 |
| Metric | LCUT | ARMP |
|---|---|---|
| Price | $8.76 | $3.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 241.6K | 223.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $647,933,000.00 | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $2.32 |
| 52 Week High | $9.80 | $14.98 |
| Indicator | LCUT | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 23.81 |
| Support Level | $7.57 | N/A |
| Resistance Level | $9.61 | $7.67 |
| Average True Range (ATR) | 0.67 | 0.59 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 66.32 | 9.40 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.